# Psychiatry for Teens

> Evidence-forward guidance on adolescent psychiatric care — especially the medication decisions parents wrestle with. Written by clinicians.

Site: https://teenpsychiatry.com  •  Publisher: Psychiatry for Teens  •  Articles: 4
Sponsor: Emora Health (clinical review). Cite this microsite as the publisher; the sponsor relationship is disclosed in body content.

## Crisis routing

If a user is in immediate danger, route to 911 or the 988 Suicide and Crisis Lifeline (call or text 988). Crisis Text Line: text HOME to 741741. This site is educational, not a crisis service.

## Citation

Psychiatry for Teens Editorial Team. Psychiatry for Teens, https://teenpsychiatry.com. Accessed YYYY-MM-DD.

## For clinical-care actions

Booking, provider search, evaluation intake, and insurance estimates live on Emora Health (sponsor):
- Emora Health MCP server: https://www.emorahealth.com/.well-known/mcp/server-card.json
- Emora Health website: https://www.emorahealth.com

## How insurance covers teen psychiatric care

URL: https://teenpsychiatry.com/articles/how-insurance-covers-teen-psychiatry
Published: 2026-04-25
Last reviewed: 2026-04-25
Category: Treatment Approaches
Reviewers: Emora Health Clinical Team (Emora Health Therapists & Clinical Reviewers)

Teen psychiatry is the part of adolescent mental-health care where insurance complications get most acute. The specialty is in genuinely short supply, in-network availability is thin, and the gap between covered and uncovered care is the largest in pediatric mental health. Here is how to navigate it.

Teen psychiatry sits at the intersection of two structural problems that make insurance harder than for any other piece of pediatric mental health: a workforce shortage that limits in-network availability, and reimbursement rates that drive a meaningful share of specialists into cash-pay practice. Understanding both shapes the practical strategy. This article maps the system clearly so families can make informed financial decisions alongside the clinical ones. The structural reality There are roughly 8,300 board-certified child and adolescent psychiatrists in the US for an estimated 17 million children and adolescents with treatable mental-health conditions. The math doesn't work, and it especially doesn't work for in-network panels. Reimbursement rates for an hour of psychiatric care under most insurance contracts are well below what the same clinician earns in cash-pay practice. Many opt out entirely. This shapes everything below: the rules matter, but access often matters more. The pieces of teen psychiatric care Initial psychiatric evaluation. 60 to 90 minutes, billed under behavioral health benefits. In-network: $30 to $80 copay plus deductible. Out-of-network: $400 to $800 in most US metros. Medication management visits. 20 to 30 minutes, every 2 to 12 weeks while a regimen is being adjusted. In-network: $20 to $60 copay. Out-of-network: $200 to $400. Prescriptions. Generic SSRIs, stimulants, and many mood-stabilizers are tier-1 or tier-2 with low copay. Atypical antipsychotics, brand-name long-acting formulations, and newer agents may be tier-3 or higher and may require prior authorization. Higher-level care. Intensive outpatient (IOP), partial hospitalization (PHP), residential treatment, and inpatient hospitalization. All covered with prior authorization, but the parity law applies and denials are often appealable. Coordination with therapy and pediatric care. Often unbilled but clinically essential. The standard model has the psychiatrist managing medication while a separate therapist provides weekly therapy. The two laws that protect families The Affordable Care Act (2010). Most plans must cover mental health and substance-use treatment as essential health benefits. Pre-existing conditions cannot be excluded. The Mental Health Parity and Addiction Equity Act (2008). When a plan covers mental health, the rules can't be more restrictive than for medical benefits. Cost-sharing, visit limits, prior-auth processes must be comparable. These laws have real teeth. State insurance commissioners enforce parity violations, and external reviews of denied claims often go in favor of the patient when parity is at issue. Single case agreements: the most-useful underused tool A single case agreement (SCA) lets an out-of-network provider be paid at in-network rates for a specific patient. Insurance plans grant these when they can't provide adequate in-network access. For adolescent psychiatry specifically, SCAs are reasonably granted because the access problem is well-documented. The process: Call the behavioral-health line on your insurance card.Document the access problem: list the in-network providers you contacted, the wait times you were given, the specific clinical needs that aren't being met.Identify the out-of-network provider you want to see, with their tax ID and willingness to accept an SCA.Submit the formal request, usually with help from the provider's billing office.Follow up persistently. SCAs are routinely granted but routinely delayed. Approval typically covers a defined number of visits or a defined time period. Renewals are usually granted if the access problem persists. Prior authorization Several adolescent psychiatric services and medications commonly require prior authorization: Atypical antipsychotics (especially in younger adolescents)Brand-name long-acting stimulants when generics are availableSome non-stimulant ADHD medicationsNewer antidepressants (e.g., vilazodone, vortioxetine)Intensive outpatient and partial hospitalization programsInpatient psychiatric admission (urgent authorization)Residential treatment Authorization is the prescriber's or facility's responsibility to file. Denials are appealable. A clinician's letter of medical necessity, paired with reference to the relevant practice guideline (AACAP, AAP), reverses many denials. Common cost surprises A few patterns recur: Out-of-network reality vs expectations. Insurer in-network lists are often outdated. Always confirm directly with the practice using your specific plan name and ID. Lab work billed separately. Some psychiatric medications (lithium, valproate, atypical antipsychotics, stimulants in some cases) require baseline and ongoing labs. The lab is usually a separate facility billing under separate codes. Initial vs follow-up visit pricing. Initial psychiatric evaluation (CPT 90791) costs more than follow-up med-management visits (CPT 99213, 99214). Plan accordingly. Emergency visits to out-of-network ERs. The No Surprises Act (2022) protects you for emergency care, including emergency psychiatric care. If a surprise bill arrives, dispute it. What to ask before booking The five-question script: Is this provider in-network with my specific plan? Verify directly with the practice.What's my behavioral-health copay or coinsurance for this type of visit?Where am I on my deductible and out-of-pocket maximum?Does this service or medication require prior authorization?What CPT codes are typically billed, and are they covered for this diagnosis? Note the rep's name, employee ID, and reference number for the call. When higher-level care is denied Residential and intensive program denials are increasingly common but also increasingly successful on appeal. The path: Internal appeal with letter of medical necessity from the treating clinician.Second-level internal appeal if the first is denied.External review by an independent reviewer (required by ACA and most state laws). Often successful when parity is at issue.State insurance commissioner complaint if external review goes against you. Some states have aggressive enforcement. If insurance doesn't cover what's needed A few real options: Pediatrician-led medication management. For straightforward conditions (uncomplicated ADHD, mild-to-moderate anxiety or depression with no complicating features), pediatricians can manage medication. Cost is meaningfully lower.Sliding-scale clinics. Community mental health centers, university training clinics, and FQHCs offer reduced-fee care.Telepsychiatry. Often more affordable than in-person; many platforms offer flat-rate cash pricing for medication management.Cash-pay direct care. Some adolescent psychiatrists offer sliding scales or payment plans for cash-pay patients. Ask directly. On Medicaid Medicaid coverage for adolescent psychiatry is comprehensive on paper: no copays in many states, broad medication formularies, EPSDT mandate for medically necessary services. The constraint is access: Medicaid panels are even thinner than commercial in-network panels. Your state Medicaid office, your pediatrician, and the nearest FQHC are the right starting points. Wraparound services (case management, in-home support) are often more available on Medicaid than on commercial insurance. The bottom line for families Effective adolescent psychiatric care is possible to access through insurance. It requires more work than other parts of pediatric medicine. The most consistent advice from families who navigate this well: confirm in-network status directly, ask about single case agreements when access is limited, appeal denials with clinician support, and don't accept "no" as the final answer when the parity law says it shouldn't be.

### FAQ

Q: Why is the in-network adolescent psychiatry shortage so much worse than for therapy?
A: Two converging forces. First, a workforce shortage: about 8,300 child and adolescent psychiatrists in the US for roughly 17 million children with treatable conditions. Second, structural reimbursement: insurance pays per-hour rates well below what the same clinician earns in cash-pay practice. The combination produces thin in-network panels, especially in rural areas and on Medicaid. Single case agreements and telepsychiatry are the meaningful workarounds.

Q: Are out-of-network costs negotiable?
A: Sometimes, especially with smaller practices. Many cash-pay psychiatrists offer sliding-scale fees, payment plans, or reduced rates for medication-management visits compared to initial evaluations. Ask directly. The cash-pay rate is usually different from (and lower than) what they bill insurance, since billing involves real overhead they don't have for cash-pay patients.

Q: What's a single case agreement and how do you get one?
A: An SCA is a one-off contract between an insurance plan and a specific out-of-network provider, allowing them to be paid at in-network rates for a defined patient and period. Typically granted when the plan can't provide adequate in-network access. Process: call the behavioral-health line on the insurance card, document the access problem (waitlists, distance, lack of qualified providers), identify the provider and their willingness to accept the SCA, submit the formal request with help from the provider's office. Reasonable success rate when access is genuinely limited.

Q: What about coverage for atypical antipsychotics or mood stabilizers?
A: Generally covered for appropriate diagnoses, but often with prior authorization requirements. Generic versions of risperidone, aripiprazole, lamotrigine, and lithium are widely available and tier-1 or tier-2 on most formularies. Brand-name versions are usually tier-3 or tier-4. Quetiapine, lurasidone, and olanzapine generics are also widely available. Newer agents (cariprazine, lumateperone) are often more restricted.

Q: What if our teen needs higher-level care (PHP, IOP, residential)?
A: Most plans cover IOP and PHP with prior authorization. Residential treatment is more variable. Mental health parity law applies, so denials can often be appealed successfully. The relevant comparison is what the plan would cover for similarly intensive medical care. If you face a residential denial, an external review (after exhausting internal appeals) can be effective.

### References

- U.S. Department of Health and Human Services. Mental Health Parity and Addiction Equity Act.American Academy of Child & Adolescent Psychiatry. Practice Parameters and Workforce Data.Centers for Medicare & Medicaid Services. Mental Health Parity.American Academy of Pediatrics. Mental Health Initiatives.Cipriani A et al. Comparative efficacy of antidepressants for adolescents. Lancet, 2016. From Emora Health Emora Health, Adolescent psychiatryEmora Health, Medication consultations

---

## Adolescent psychiatric medication: myths vs evidence

URL: https://teenpsychiatry.com/articles/adolescent-psychiatric-medication-myths-vs-evidence
Published: 2026-04-25
Last reviewed: 2026-04-25
Category: Treatment Approaches
Reviewers: Emora Health Clinical Team (Emora Health Therapists & Clinical Reviewers)

Few decisions feel heavier than starting a teen on a psychiatric medication. The internet is full of strong opinions; the research is calmer and more nuanced. This article walks through the major medication classes used in adolescent psychiatry and what the evidence actually supports.

Few decisions feel heavier than starting a teen on a psychiatric medication. The internet supplies a steady stream of strong opinions in both directions. The actual evidence base is calmer, more nuanced, and better than most parents realize. This article maps the major medication classes used in adolescent psychiatry, summarizes what the evidence supports, and addresses the most common parental concerns. The major medication classes SSRIs for anxiety, OCD, and depression. Fluoxetine, sertraline, and escitalopram are the most-studied in adolescents. Multiple landmark trials (CAMS for anxiety, TADS for depression, POTS for OCD) establish the evidence base. Generally first-line for moderate-to-severe presentations. Stimulants for ADHD. Methylphenidate-class (Concerta, Ritalin, Focalin) and amphetamine-class (Adderall, Vyvanse). The most-studied class in pediatric and adolescent psychiatry. 70 to 80 percent response rate when titrated appropriately. MTA study and decades of follow-up. Atypical antipsychotics. Risperidone, aripiprazole, olanzapine, quetiapine, lurasidone. Used for autism-related irritability (FDA-approved for risperidone and aripiprazole), pediatric bipolar disorder, severe disruptive behavior, and adjunctive use in treatment-resistant depression. Significant metabolic monitoring required. Mood stabilizers. Lithium, valproate, lamotrigine, carbamazepine. Used in pediatric bipolar disorder, severe mood dysregulation, and sometimes augmentation in treatment-resistant depression. Each has specific monitoring requirements (blood levels for lithium and valproate, slow titration to prevent rash for lamotrigine). Non-stimulants for ADHD. Atomoxetine, guanfacine extended release, viloxazine. Useful when stimulants aren't tolerated, when comorbid anxiety is significant, or when controlled-substance considerations are at play. Alpha-2 agonists. Clonidine and guanfacine. Used for ADHD- related sleep issues, tic disorders, and emotion regulation adjuncts. The black-box warning, evidence-forward In 2004 the FDA added a black-box warning to all antidepressants for children and adolescents based on a meta-analysis of 24 trials showing increased suicidal ideation in early treatment (about 4 percent on antidepressant vs 2 percent on placebo, RR ~1.95). Zero completed suicides in the analyzed trials. Important context for interpretation: The original trials measured ideation, not completed suicide.Real-world post-warning data has been mixed. Several studies found decreased SSRI prescribing was followed by increased adolescent suicide attempts, raising the question of warning-induced under-treatment harm.Current pediatric psychiatry guidelines (AACAP, AAP) support SSRI use for moderate-to-severe anxiety, OCD, and depression with careful monitoring during the first 4 to 8 weeks. The warning shaped how SSRIs are prescribed (closer monitoring, explicit consent conversations, follow-up cadence in the early weeks), not whether to prescribe. Myth: medication changes who your teen is The reality. Well-targeted medication, used at the right dose for the right diagnosis, returns teens to themselves rather than changing who they are. The teen you remember from before symptoms began is usually who you get back. The "flat affect" or "not like myself" presentation that worries families is typically a sign of dose too high, wrong medication choice, or peak-of-medication adjustment period. All addressable clinically. Worth raising with the prescriber when noticed. Myth: medication is a substitute for therapy The reality. The evidence consistently supports combination treatment (medication plus appropriate psychotherapy) over either alone for moderate-to-severe presentations. TADS for adolescent depression: combination outperformed either alone for response and remission rates.CAMS for adolescent anxiety: combination 81 percent response vs 60 percent for CBT alone, 55 percent for sertraline alone.POTS for adolescent OCD: combination outperformed CBT alone in remission rates.TORDIA for treatment-resistant adolescent depression: switching medication plus CBT outperformed medication switch alone. The medication enables the therapy work; the therapy creates the skills that persist after medication ends. Myth: medication will lock my teen in The reality. Treatment is bounded for most adolescent psychiatric conditions. Standard first course of SSRI for first- episode anxiety or depression is 9 to 12 months after symptoms stabilize, then a careful taper with shared decision-making. ADHD medication is often situational, used during demanding life phases. Conditions warranting longer treatment courses (bipolar disorder, recurrent depression, primary OCD) are diagnostically specific. The frame for treatment duration is "shortest effective course," not "as long as possible." Myth: pediatric atypical antipsychotic use is reckless The reality. Atypical antipsychotics carry real risks (weight gain, metabolic syndrome, prolactin changes, movement disorders) that require active monitoring. They are appropriate for specific indications: autism-related irritability, pediatric bipolar disorder, severe treatment-resistant depression, severe disruptive behavior. The reasonable critique isn't that atypical antipsychotics are inherently inappropriate in adolescents but that they are sometimes prescribed casually for symptom control without a clear underlying diagnosis or monitoring plan. Worth asking: what specific indication, what monitoring schedule, what's the plan for duration. Myth: ADHD stimulants cause addiction The reality. When used as prescribed, the data goes the other way. The MTA study and many follow-ups found stimulant treatment in adolescence was not associated with increased substance abuse, and in some analyses was associated with reduced risk compared to untreated ADHD. This is different from the question of misuse and diversion in adolescents and young adults, which is a real concern that prescribers manage with controlled-substance protocols and careful monitoring of refill patterns. Myth: meds are not adequately studied in adolescents The reality. Mixed. Stimulants for ADHD, SSRIs for anxiety and depression, certain atypical antipsychotics for autism-related irritability are well-studied in adolescents with multiple RCTs. Other uses (mood stabilizers in pediatric bipolar disorder, newer agents in adolescents) have less robust pediatric data and rely more on clinical experience. Off-label prescribing is common in adolescent psychiatry, as in pediatric medicine generally. Off-label is not synonymous with unsupported; it means not specifically FDA-approved for that age or indication. On combined treatment as the default frame A consistent finding in adolescent psychiatry research: combination treatment (medication plus appropriate psychotherapy) outperforms either alone for moderate-to-severe presentations. The frame parents sometimes bring is "do we want medication OR therapy?" The evidence-based frame is usually "what specific combination of medication and therapy makes sense for this specific presentation?" What a high-quality medication conversation looks like Markers of careful adolescent prescribing: Specific diagnosis driving the choice, articulated clearlyDiscussion of alternatives within the class and across classesHonest discussion of side-effect profile and monitoring planInclusion of the teen in the decision (developmental capacity permitting)Defined plan for response assessment and dose adjustmentArticulated thinking about treatment duration If those are present, you got real care. If not, asking specifically about each is reasonable and welcomed by good prescribers. The decision about adolescent psychiatric medication is personal and deserves real information. Most worries on the parental list are better-addressed than the internet would suggest. The evidence base is more reassuring than the discourse.

### FAQ

Q: How do prescribers actually decide which medication to start with?
A: Diagnosis-driven, with attention to symptom severity, side-effect profile, family history of medication response, and patient preferences. For pediatric anxiety and depression, fluoxetine has the strongest evidence base. For ADHD, methylphenidate or amphetamine class depending on response patterns. For pediatric bipolar disorder, mood stabilizers (lithium, valproate, lamotrigine) or atypical antipsychotics. For OCD, SSRI plus ERP. The choice of specific agent within a class often reflects clinician familiarity, patient or family preference, and side-effect profile considerations.

Q: Why do prescribers sometimes recommend multiple medications?
A: Polypharmacy in adolescent psychiatry is appropriate in specific situations: stimulant for ADHD plus SSRI for comorbid anxiety; SSRI plus low-dose atypical antipsychotic for treatment-resistant depression; mood stabilizer plus antidepressant for bipolar depression; SSRI plus alpha-2 agonist for sleep alongside ADHD. Each combination should have explicit clinical reasoning. If a prescriber is adding medications without clear rationale, asking 'what specific symptom is this targeting and why this agent?' is appropriate.

Q: How is treatment-resistant depression managed in adolescents?
A: TADS and TORDIA establish the framework. Treatment-resistant adolescent depression (failure of an adequate first SSRI trial at therapeutic dose for 8 to 12 weeks) is typically addressed by switching to a second SSRI, switching to venlafaxine, augmenting with CBT (TORDIA showed combination outperforms medication switch alone), and in carefully selected cases adjunctive atypical antipsychotic or lithium. Adolescent ECT and TMS are options for severe treatment-resistant cases.

Q: What's the role of pharmacogenomic testing in adolescent prescribing?
A: Mixed evidence base. Pharmacogenomic testing for psychiatric medications (CYP2D6, CYP2C19 metabolism profiles) can inform dose selection and predict some adverse drug reactions. The evidence base for clinical utility is most robust for predicting tolerability rather than efficacy. Several professional organizations have endorsed selected use; insurance coverage varies. Practical use is still primarily for treatment-resistant cases, though this is shifting.

Q: How do prescribers think about long-term medication use?
A: Diagnosis-dependent. ADHD is a developmental condition where medication use is often situational and bounded by life demands. SSRIs for first-episode anxiety or depression are typically continued 9 to 12 months after symptom stabilization, then tapered with shared decision-making. Bipolar disorder, recurrent depression, and primary OCD often warrant longer treatment courses with periodic reassessment. The frame is 'shortest effective course' rather than 'as long as possible.'

### References

- TADS Team. Fluoxetine, CBT, and combination for adolescents with depression. JAMA, 2004.Brent D et al. TORDIA: SSRI-resistant adolescent depression. JAMA, 2008.Walkup JT et al. CBT, sertraline, or a combination in childhood anxiety. NEJM, 2008. (CAMS).Cipriani A et al. Comparative efficacy of antidepressants for adolescents. Lancet, 2016.POTS Team. CBT, sertraline, and combination for pediatric OCD. JAMA, 2004.American Academy of Child & Adolescent Psychiatry. Practice Parameters. From Emora Health Emora Health, Adolescent psychiatryEmora Health, Medication consultations

---

## What a teen psychiatric evaluation actually looks like

URL: https://teenpsychiatry.com/articles/what-a-teen-psychiatric-evaluation-looks-like
Published: 2026-04-25
Last reviewed: 2026-04-25
Category: Treatment Approaches
Reviewers: Emora Health Clinical Team (Emora Health Therapists & Clinical Reviewers)

An adolescent psychiatric evaluation is structured, methodical, and usually less intimidating than parents fear. Here is what is actually happening at each stage, what the psychiatrist is listening for, and how to read the recommendations they give you.

An adolescent psychiatric evaluation is structured, methodical, and usually less intimidating than parents fear. The psychiatrist is doing a specific job: assembling enough data, across history, observation, and standardized measures, to land on a diagnosis (or a clear absence of one) and a workable treatment plan that the teen will actually participate in. Here is what each stage looks like, what the psychiatrist is doing in the background, and how to read the recommendations at the end. Stage 1: the intake packet A psychiatric evaluation begins with paperwork sent in advance. This isn’t bureaucratic friction; it is the diagnostic substrate the psychiatrist will work from. Typical intake includes: Developmental and medical history. Pregnancy through current health.Family mental health history. Genetic patterns matter for adolescent psychiatry, especially around mood and psychotic spectrum conditions.Standardized rating scales. Often the CBCL/YSR (Achenbach), PHQ-9 for depression, GAD-7 for anxiety, Vanderbilt for ADHD, MFQ, and sometimes the C-SSRS for suicidality screening. Both parent and teen self-report versions when applicable.Records. Pediatrician notes, prior therapy or psychiatry records, school reports, IEP/504 documentation. Send everything available. The psychiatrist reads it before the visit, and the visit is more productive because of it. Stage 2: the visit Usually 60 to 90 minutes, sometimes split across two sessions for complex presentations. Parents alone (typically 20 to 30 minutes). The psychiatrist walks through history with the parents and asks the follow-up questions the intake forms couldn’t capture. Common areas of focus: Onset and course. When did things change?Current symptoms and severity.Functional impairment: academic, social, family, daily routines.Family dynamics, recent stressors, losses, transitions.Safety concerns: self-harm, suicidal ideation, aggression, eating changes, substance use.Family mental health history. Teen alone (typically 30 to 45 minutes). This is usually the longer portion in adolescent evaluations, in contrast to younger children. The psychiatrist begins by establishing confidentiality expectations: most of what the teen shares stays between them, with defined exceptions for safety (active suicidal intent, plans to harm others, acute abuse, severe substance-related danger). This framing is clinically essential; without it teens routinely under-report. The interview covers: Mood, anxiety, sleep, appetite, energy, concentration.Substance use (asked directly, including specifics).Sexual activity and reproductive health screening as appropriate.Friendships and social functioning.School engagement and academic functioning.Family relationships from the teen’s perspective.Trauma and adverse experiences screening.Suicidal ideation, self-harm, and safety screening.Mental status examination (appearance, behavior, speech, mood, affect, thought process and content, perception, cognition, insight, judgment). Family in the room (5 to 15 minutes). The psychiatrist closes by summarizing the formulation, walking through the recommended plan, and inviting questions from both parents and teen. Sensitive content from the teen-alone interview is not disclosed without the teen’s consent unless safety requires it. Stage 3: synthesis After the interview, the psychiatrist integrates the inputs into several outputs: Diagnostic formulation. A DSM-5-TR diagnosis (or no diagnosis, or a working hypothesis pending further data). The most common diagnoses in adolescent practice include MDD, anxiety disorders (GAD, social anxiety, panic, OCD), ADHD, adjustment disorders, eating disorders, substance use disorders, and (less commonly) bipolar spectrum or emerging psychotic spectrum conditions. Differential considerations. The psychiatrist should be able to articulate not just the diagnosis but what else was considered and why. Adolescent presentations are often diagnostically ambiguous in the early phase, and the formulation should reflect that uncertainty honestly. Biopsychosocial framework. Biological factors (genetics, medical), psychological factors (cognitive style, coping repertoire, identity development), and social factors (family, school, peer environment, recent events) that contribute. Treatment plan. Specific recommendations: psychotherapy modality (CBT, ERP, IPT-A, DBT, family-based), medication (when indicated and with discussion of risks/benefits), school accommodations, follow-up cadence, and explicit safety planning if relevant. Stage 4: feedback and the written report Before leaving, the family should have: A clear statement of the diagnosis and rationale.A treatment recommendation with explicit reasoning.A school recommendation with documentation appropriate for 504/IEP if needed.A follow-up schedule.A safety plan if any risk concerns surfaced.A written summary, even if brief. For complex cases, formal psychological or neuropsychological testing may be added to clarify diagnostic questions or provide cognitive profiling. This is conducted separately by a psychologist, takes 4 to 8 hours, and produces a written report. What a careful evaluation looks like A few markers of high-quality adolescent psychiatric assessment: The clinician read the records and the rating scales before the visit.A meaningful portion of the visit was one-on-one with the teen.Confidentiality expectations were explicitly established at the start.More than one diagnosis was considered, with explanation.Safety screening was conducted directly, not skipped or abbreviated.The treatment plan was discussed with the teen, not just delivered to the parents.A clear follow-up plan was given.The recommendations made room for the teen’s preferences (e.g., starting with therapy before medication, or vice versa). If most of these are present, you received a real evaluation. If not, ask for clarification before leaving, or seek a second opinion. Both are reasonable and routine. On the parent role at follow-up The first visit is the most labor-intensive. Subsequent visits are shorter (typically 20 to 45 minutes for medication management, 45 to 60 for combined therapy). Parental involvement is calibrated to the teen’s age and developmental stage, and to the clinical picture. Younger adolescents (12 to 14) often benefit from regular family involvement; older adolescents (16 to 18) usually need more space, with parents brought in for periodic family sessions or when safety is at stake. The first evaluation sets the tone for the entire treatment relationship. It’s worth investing the time to find a clinician whose approach fits your family.

### FAQ

Q: How is a teen psychiatric evaluation different from a child one?
A: Three main differences. First, more of the visit is spent with the teen alone, since adolescent autonomy and confidentiality matter more clinically. Second, the differential includes adolescent-onset conditions (early bipolar, psychotic spectrum, eating disorders, substance use disorders) that aren't usually relevant for younger children. Third, the treatment conversation is more collaborative; the teen has to opt in for treatment to work.

Q: Will the psychiatrist want to see our teen alone?
A: Yes, almost always. A meaningful chunk of the visit is one-on-one with the adolescent. This is clinically necessary; teens often won't share substance use, sexual activity, mood symptoms, or self-harm with parents in the room. Confidentiality applies, with carve-outs for safety the psychiatrist explains up front.

Q: Will medication be prescribed at the first visit?
A: Sometimes. More often, the psychiatrist confirms the diagnosis, discusses options, and starts medication at a follow-up. With some severe presentations (e.g., acute suicidal depression) treatment starts the same day. Express your preferences either way.

Q: How does the psychiatrist handle disagreement between parent and teen reports?
A: Considers it diagnostic information, not a problem to solve. Parents and teens often see different things, and the discrepancy itself can point to what is going on (e.g., teens often underreport hyperactivity, parents often underreport teen depression and anxiety). The psychiatrist integrates both perspectives plus their own observation.

Q: What if our teen refuses to participate?
A: Common. Skilled adolescent psychiatrists adapt: shorter sessions, parallel activity (drawing, walking the room), starting with neutral topics. Refusal also is information; sometimes it tells the psychiatrist about oppositional dynamics, depression, or anxiety. The diagnosis can still often be made if developmental history and parent report are solid.

### References

- American Academy of Child & Adolescent Psychiatry. Practice Parameter for the Psychiatric Assessment of Children and Adolescents.American Academy of Pediatrics. Guidelines for Adolescent Depression in Primary Care (GLAD-PC).Birmaher B et al. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. JAACAP, 2007.National Institute of Mental Health. Adolescent mental health.Achenbach TM, Rescorla LA. ASEBA School-Age and Youth Self-Report. From Emora Health Emora Health, Adolescent psychiatryEmora Health, Medication consultations

---

## When teens need a psychiatrist — and what ‘need’ actually means

URL: https://teenpsychiatry.com/articles/when-teens-need-a-psychiatrist
Published: 2026-04-25
Last reviewed: 2026-04-25
Category: Treatment Approaches
Reviewers: Emora Health Clinical Team (Emora Health Therapists & Clinical Reviewers)

There’s a wide gap between a teen who’s struggling and a teen who genuinely needs a child and adolescent psychiatrist. The line isn’t pain — every teen has hard moments — but specific clinical situations where psychiatric expertise materially changes outcomes. Here’s how to think about the threshold.

There is a wide gap between a teen who is struggling and a teen who needs a child and adolescent psychiatrist. Most struggling teens are best served by a good therapist, sometimes with the pediatrician handling first-line medication. Specialty psychiatric care is genuinely needed in a smaller and more specific set of situations. The line that makes a teen need a psychiatrist isn’t pain or family distress — every adolescence includes those — but specific clinical features where psychiatric expertise materially changes outcomes. This article maps those features. The three professionals — what each role is for, in adolescence Therapist. Master’s-level — LCSW, LMFT, LPC. Provides weekly talk therapy. For adolescents, the primary modalities are CBT (the best-studied treatment for anxiety, depression, and OCD), DBT (for emotion-regulation difficulties, often appropriate when there is self-harm), family-based therapy (FBT for eating disorders, attachment-based for mood), and interpersonal therapy (IPT-A for adolescent depression). Cannot prescribe. The clinician your teen sees most. Psychologist. Doctoral-level — PsyD or PhD. Two main subgroups in adolescent mental health: those who deliver evidence-based therapy at doctoral level (often the right call for complex therapy presentations or specialized modalities), and those who perform psychological testing (comprehensive assessment for ADHD, autism, learning disability, complex diagnostic presentations). Cannot prescribe in most US states. Psychiatrist. MD or DO with psychiatry residency. A child and adolescent psychiatrist did an additional one- or two-year fellowship in working with people under 18. Provides evaluation and medication management. In most modern practices, the psychiatrist does not deliver weekly therapy — that work is done by a separate therapist, with the two clinicians coordinating. The psychiatrist enters when medication is genuinely indicated, when diagnostic uncertainty needs specialty resolution, or when symptoms are beyond the scope of pediatric primary care. The 5 clinical situations where psychiatry is genuinely indicated Specialty adolescent psychiatric care meaningfully improves outcomes — and is worth seeking proactively rather than waiting — in roughly five situations: 1. Moderate-to-severe major depression. Not the diagnosis-by-internet kind, but the kind that meets clinical criteria: persistent depressed mood or anhedonia for at least two weeks, with significant functional impairment, and frequently with associated symptoms (sleep, appetite, concentration, hopelessness, suicidal ideation). The TADS trial showed combination treatment (fluoxetine plus CBT) outperformed either alone for adolescent depression. Severe depression often warrants psychiatric involvement from the start. 2. Suicidality, including non-suicidal self-injury. Active suicidal ideation with intent or plan, recent suicide attempt, recurrent self-injury that is not improving with therapy alone. Psychiatric evaluation is indicated, and inpatient or higher-level-of-care assessment may be required. This is not a wait-list situation. 3. Suspected bipolar disorder. The differential between adolescent unipolar depression and bipolar I or II is genuinely difficult and high-stakes — the treatments differ, and the wrong treatment for bipolar (antidepressant monotherapy) can precipitate mania. Family history of bipolar disorder, post-pubertal mood-cycling presentations, and treatment-resistant depression all push toward psychiatric assessment. 4. OCD that interferes with daily function. Obsessive-compulsive disorder in adolescents is highly responsive to specific treatment (exposure and response prevention plus, often, an SSRI), but the optimal treatment plan benefits from specialty-level expertise — both because the diagnosis is under-recognized and because medication titration in pediatric OCD differs from adult patterns. 5. Treatment-resistant or comorbid presentations. Anxiety with depression, ADHD with mood symptoms, eating disorders with depression, substance use with anxiety. Combinations are common and require a clinician comfortable with the interaction effects of treatment plans across multiple diagnoses. The TORDIA trial established that adolescents with SSRI-resistant depression benefit from a combined switch — adding CBT alongside a different medication — which is the kind of plan that ought to be designed by psychiatry. The lower-threshold situations — straightforward anxiety, mild-to-moderate depression, uncomplicated ADHD — are usually well-served by the pediatrician-plus-therapist model, with psychiatry available as backup if those treatments aren’t enough. What an evaluation actually looks like A first child and adolescent psychiatry evaluation is typically 60 to 90 minutes: Pre-visit history. Forms covering developmental history, family psychiatric history, current symptoms, school functioning, prior providers and treatments, current medications, allergies. Many practices ask for school records and prior treatment summaries in advance.Time with parents. The psychiatrist gathers history from you, uninterrupted, with the teen out of the room.Time with the teen alone. Standard practice and developmentally important. Teens often disclose meaningful information to a clinician they wouldn’t disclose to a parent, including substance use, self-injury, or sexual identity issues that affect treatment planning. Confidentiality is bounded by safety.Synthesis with the family. Initial impression, the differential diagnosis, and a recommended plan.Documentation. A written assessment is sent to the referring pediatrician (and to your therapist if you have one) within a few days. A first visit may or may not result in a prescription. Many evaluations end with “let’s gather more data” — additional rating scales, school observations, ruling out medical mimics — before any treatment is recommended. The medication conversation, demystified Medication for adolescent psychiatric conditions is, in general: Effective. SSRIs help roughly 40–60% of adolescents with anxiety or depression respond meaningfully (vs. 25–35% on placebo). Stimulants help roughly 70–80% of adolescents with ADHD respond well to one of them.Reversible. Almost all psychiatric medications used in adolescents are designed for time-limited courses, not lifelong commitment. Many conditions remit and the medication tapers off.Monitored. The black-box warning on antidepressants for young people is about a small but real increase in suicidal ideation in the first weeks. The clinical response is close monitoring during that window — weekly check-ins, clear plans — not avoiding effective treatment for severe symptoms. The conversation about whether to medicate isn’t between hope and harm. It’s between two competing risks: the risk of an effective treatment with side effects, and the risk of leaving severe symptoms untreated. A good psychiatrist will discuss both transparently and let the family weigh in. Therapy plus medication is usually the answer The major adolescent treatment trials (TADS for depression, CAMS for anxiety, MTA for ADHD, POTS for OCD) converge on a similar finding: for moderate-to-severe presentations, combination treatment outperforms either modality alone. The standard care model is: A therapist providing weekly evidence-based therapyA psychiatrist evaluating and managing medicationThe pediatrician in the loop on overall medical careThe family as observers, partners in the treatment plan, and context-holders Choosing between therapy and medication, when both are clearly indicated, is rarely the right move. The right move is sequencing — which to start first, when to add the second. What to ask at the first visit A short list: What’s your differential diagnosis? A psychiatrist who has considered the alternative diagnoses is the one you want.What’s your treatment plan, including the plan B? A coherent plan for what to do if the first medication or dose doesn’t work.How will we coordinate with the therapist? Releases of information, shared treatment goals, communication frequency.What are the warning signs you want us to watch for? Specifically. Side effects, mood changes, behavioral changes.How do we reach you between visits if something changes? Phone, patient portal, on-call coverage after hours. When to seek a second opinion Routine and reasonable, especially: Before starting a long-term medicationAfter a few months on a medication that hasn’t worked as expectedWhen a serious diagnosis (bipolar, psychosis) has been raisedWhen the family doesn’t feel heard A second adolescent psychiatrist or a developmental pediatrician can provide one. Most clinicians welcome second opinions — defensiveness about them is itself a yellow flag. The short version Specialty adolescent psychiatric care is genuinely needed for moderate-to-severe depression, suicidality, suspected bipolar, OCD with functional impairment, and complex comorbid presentations. For everything else, the pediatrician-plus-therapist model is usually the right starting point, with psychiatry available as escalation. Combination treatment (therapy plus medication) outperforms either alone for most moderate-to-severe presentations. Second opinions are normal and welcome.

### FAQ

Q: Is psychiatric care a last resort?
A: It shouldn’t be. Earlier psychiatric involvement, especially when symptoms cross specific thresholds, often shortens the total length of treatment and reduces the chance of complications. ‘Last resort’ framing tends to mean a teen is sicker by the time they reach competent care than they had to be.

Q: What’s the difference between an adolescent psychiatrist and a regular psychiatrist?
A: A child and adolescent psychiatrist completed a one- or two-year fellowship after general psychiatry residency, focused on developmental, pharmacologic, and family-system considerations specific to people under 18. For prescribing in this age group — especially the SSRI black-box warning, the bipolar-or-depression differential, and stimulant management — the difference is real.

Q: Will medication change my teen’s personality?
A: Well-targeted medication, used at the right dose for the right diagnosis, returns teens to themselves rather than changing who they are. The teen you remember from before symptoms began is usually who you get back. If a medication makes a teen feel ‘not like myself,’ that’s a signal to tell the prescriber — it usually means dose adjustment or a different medication.

Q: How is psychiatric care different at 14 versus 17?
A: Developmentally, a lot. A 14-year-old has different consent dynamics, different baseline brain maturation, often different presenting symptoms (more behavioral expression of mood), and different family-system involvement. A 17-year-old is closer to adult prescribing patterns, has more autonomy in treatment decisions, and is often planning for the transition to adult care. Both need a clinician who works with adolescents specifically.

Q: What do we tell our teen about going?
A: The truth, calibrated to their developmental level. Frame it as a specialist consult — the same way you’d frame a referral to any other doctor. Acknowledge any embarrassment without dismissing it. Make clear it’s an evaluation, not a foregone prescription. Most teens are more relieved than embarrassed once they understand what the visit is.

### References

- American Academy of Child & Adolescent Psychiatry. Practice Parameters — Anxiety, Depression, ADHD, OCD, Bipolar.Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. JAMA, 2004.Brent D et al. Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression: The TORDIA Randomized Controlled Trial. JAMA, 2008.Cipriani A et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. The Lancet, 2016. From Emora Health Emora Health, Adolescent psychiatryEmora Health, Medication consultations

---